Health Economics›Non-small cell lung cancer›Advanced or metastatic disease ALK inhibitor-naive

Advanced or metastatic disease ALK inhibitor-naive

Non-small cell lung cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Crizotinib monotherapy Variant #01	ALK	R 50 221	28d	11.1 mo	—	2	R 100 441 PFS proxy	12
Brigatinib monotherapy Variant #01	ALK	R 45 153	28d	21.7 mo	—	2	R 90 305 PFS proxy	2
Ceritinib monotherapy Variant #01	ALK	R 35 198	28d	11.0 mo	—	2	R 70 395 PFS proxy	2
Carboplatin and Pemetrexed Variant #01	ALK	R 14 563	21d	5.6 mo	22.5 mo	4	R 58 251 PFS proxy	18
Cisplatin and Pemetrexed Variant #01	ALK	R 13 666	21d	5.5 mo	22.5 mo	4	R 54 665 PFS proxy	20
Pemetrexed monotherapy Variant #01	ALK	R 13 225	21d	1.6 mo	—	4	R 52 900 PFS proxy	3
Docetaxel monotherapy Variant #02	ALK	R 2 921	28d	1.6 mo	—	6	R 17 529 PFS proxy	4
Alectinib monotherapy Variant #01	ALK	R 108	28d	27.0 mo	—	2	R 215 PFS proxy	7
Lorlatinib monotherapy Variant #01 Partial	ALK	—	28d	—	—	2	—	2
Ensartinib monotherapy Variant #01 Partial	ALK	—	28d	25.8 mo	—	2	—	1

10 of 10 regimens shown